Clifton Kew is a Nephrology physician affiliated with University of Alabama System. OpenAlex indexes 39 publications with 1,102 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1717 6th Ave S
Birmingham, AL 352331801
Telephone
800-822-8816Registry record last updated 2 Feb 2024.
Clinical trials
- Live Kidney Donor Study
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20241 payment
- Veloxis Pharmaceuticals, Inc.Program year20241 payment
- SANOFI-AVENTIS U.S. LLCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
41.8%Beta blocker10.2%Carvedilol79%Metoprolol Tartrate16%Metoprolol Succinate5%Part D<11 patientsCalcium channel blocker7.8%Nifedipine Er49%Amlodipine Besylate46%Diltiazem 12hr Er5%Part D<11 patients+ 9 more classes in this area
Metabolism & gastrointestinal
24.7%Corticosteroid11.2%Prednisone100%Part D≥119 patientsProton pump inhibitor10.1%Pantoprazole Sodium83%Omeprazole12%Esomeprazole Magnesium5%Part D<11 patients+ 2 more classes in this area
Anti-infectives
20.6%Short-acting sulfonamides16.9%Sulfamethoxazole-Trimethoprim100%Part D≥188 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor1.9%Valganciclovir Hcl100%Part D≥32 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2007–2007 per NIH RePORTER. The latest:
- LONG-TERM OUTCOME OF AFRICAN-AMERICAN LIVING KIDNEY TRANSPLANT DONORS
University of Alabama at Birmingham
FY2007$6,919M01RR000032
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Outcomes of Pre-Existing DSA in Highly Sensitized Kidney Transplant Recipients
American Journal of Transplantation
2025 - Diagnostic Performance of Polymerase Chain Reaction in Diagnosing BK Virus-Associated Nephropathy: A Decade-Long, Single-Center Experience
Journal of the American Society of Nephrology
2025 - Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Journal of the American Society of Nephrology
2025 - A randomized, placebo‐controlled, dose‐escalation phase I/II multicenter trial of low‐dose cidofovir for BK polyomavirus nephropathy
Transplant Infectious Disease
2024
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”